In this installment of our Guidelines International Series, we will delve into the guidelines established by the Canadian Coalition for Seniors’ Mental Health (CCSMH). The CCSMH is committed to enhancing the quality of care and support for older adults throughout Canada. Their primary focus is on bridging gaps in knowledge and practice to ensure that […]
Read More
Prurigo nodularis is a chronic skin condition that impacts an estimated 75,000 individuals in the United States (US). This condition is characterized by persistent and intense itching, significantly impacting the quality of life for those affected. Research has shown a higher prevalence of prurigo nodularis among individuals with certain comorbidities, such as mental health, endocrine, […]
Read MoreWelcome to the latest edition of our Guidelines+ Monographs Series. In this installment, we will delve into the medication aripiprazole, marketed under the brand name Abilify Asimtufii by Otsuka Pharmaceutical Co., Ltd. Abilify Asimtufii (aripiprazole) is a long-acting injectable atypical antipsychotic for the treatment of schizophrenia and bipolar I disorder. It was initially approved in […]
Read MoreWelcome to the latest edition of our Guidelines+ Monographs Series. In this installment, we will delve into the medication brexpiprazole, marketed under the brand name Rexulti by Otsuka America Pharmaceutical, Inc and Lundbeck LLC. Rexulti, an atypical antipsychotic, received initial approval in 2015. It is indicated for use as an adjunctive therapy to antidepressants for […]
Read More
September 10th marks World Suicide Prevention Day 2024, an annual event organized by the International Association for Suicide Prevention (IASP). This significant day serves as a global platform to raise awareness about the preventability of suicide. In alignment with this theme, our Guidelines Rundown Series presents a new article focusing on suicide prevention guidelines. Various […]
Read More